Cardiovascular Disease in Blacks: Can We Stop the Clock?

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2008 May 6

PMID 18453798

Citations 9

Authors

Keith C Ferdinand

Affiliations

Soon will be listed here.

Abstract

Blacks have the highest rates of hypertension and cardiovascular disease, with earlier onset, greater severity, and more target organ damage including coronary disease, heart failure, stroke, and end-stage renal disease. A major reason is the greater prevalence of other cardiovascular disease risk factors, particularly obesity, inactivity, and diabetes mellitus, along with socioeconomic differences, adherence, and achievement of goals. This review focuses on the burden of cardiovascular disease in blacks. Therapeutic lifestyle changes and pharmacologic interventions to decrease clinical events in this high-risk group are described. Intensive blood pressure control is a primary means of "stopping the clock" in the progression of cardiovascular disease and renal disease. Thiazide diuretics remain primary first-step agents, especially for uncomplicated hypertension; calcium channel blockers are also efficacious. However, renin-angiotensin system modulators may also be beneficial, especially with a diuretic, considering the high prevalence in this group of patients of compelling indications for use of such agents.

Citing Articles

Estrogen-mediated mechanisms in hypertension and other cardiovascular diseases.

Visniauskas B, Kilanowski-Doroh I, Ogola B, McNally A, Horton A, Imulinde Sugi A J Hum Hypertens. 2022; 37(8):609-618.

PMID: 36319856 PMC: 10919324. DOI: 10.1038/s41371-022-00771-0.

Ocular blood flow as it relates to race and disease on glaucoma.

Siesky B, Harris A, Vercellin A, Guidoboni G, Tsai J Adv Ophthalmol Optom. 2022; 6:245-262.

PMID: 35252630 PMC: 8896810. DOI: 10.1016/j.yaoo.2021.04.016.

Sex-, Race- and Ethnicity-Based Differences in Thromboembolic Events Among Adults Hospitalized With COVID-19.

Ilyas S, Henkin S, Martinez-Camblor P, Suckow B, Beach J, Stone D J Am Heart Assoc. 2021; 10(23):e022829.

PMID: 34845920 PMC: 9075407. DOI: 10.1161/JAHA.121.022829.

Ocular blood flow as a clinical observation: Value, limitations and data analysis.

Harris A, Guidoboni G, Siesky B, Mathew S, Vercellin A, Rowe L Prog Retin Eye Res. 2020; :100841.

PMID: 31987983 PMC: 8908549. DOI: 10.1016/j.preteyeres.2020.100841.

Prescribing patterns in the treatment of hypertension among underserved African American elderly.

Yazdanshenas H, Bazargan M, Orum G, Loni L, Mahabadi N, Husaini B Ethn Dis. 2014; 24(4):431-7.

PMID: 25417425 PMC: 4286375.

References

Bosch J, Yusuf S, Gerstein H, Pogue J, Sheridan P, Dagenais G . Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006; 355(15):1551-62. DOI: 10.1056/NEJMoa065061. View

Moser M, Lunn J . Responses to captopril and hydrochlorothiazide in black patients with hypertension. Clin Pharmacol Ther. 1982; 32(3):307-12. DOI: 10.1038/clpt.1982.165. View

Elliott W, Meyer P . Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557):201-7. DOI: 10.1016/S0140-6736(07)60108-1. View

Ferdinand K, Saunders E . Hypertension-related morbidity and mortality in African Americans--why we need to do better. J Clin Hypertens (Greenwich). 2006; 8(1 Suppl 1):21-30. PMC: 8109309. DOI: 10.1111/j.1524-6175.2006.05295.x. View

Douglas J, Bakris G, Epstein M, Ferdinand K, Ferrario C, Flack J . Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163(5):525-41. DOI: 10.1001/archinte.163.5.525. View

Svetkey L, Vollmer W, Appel L, Conlin P, Ryan D, Ard J . Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999; 159(3):285-93. DOI: 10.1001/archinte.159.3.285. View

. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23):2981-97. DOI: 10.1001/jama.288.23.2981. View

Fields L, Burt V, Cutler J, Hughes J, Roccella E, Sorlie P . The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004; 44(4):398-404. DOI: 10.1161/01.HYP.0000142248.54761.56. View

Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips R . Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006; 48(5):739-51. DOI: 10.1053/j.ajkd.2006.08.004. View

10.

Wong N, Lopez V, Tang S, Williams G . Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98(2):204-8. DOI: 10.1016/j.amjcard.2006.01.079. View

11.

. Physical activity levels among children aged 9-13 years--United States, 2002. MMWR Morb Mortal Wkly Rep. 2003; 52(33):785-8. View

12.

Ferdinand K . Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens. 2003; 16(11 Pt 2):50S-54S. DOI: 10.1016/j.amjhyper.2003.07.007. View

13.

Bosworth H, Dudley T, Olsen M, Voils C, Powers B, Goldstein M . Racial differences in blood pressure control: potential explanatory factors. Am J Med. 2006; 119(1):70.e9-15. DOI: 10.1016/j.amjmed.2005.08.019. View

14.

Ong K, Cheung B, Man Y, Lau C, Lam K . Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2006; 49(1):69-75. DOI: 10.1161/01.HYP.0000252676.46043.18. View

15.

Agodoa L, Appel L, Bakris G, Beck G, BOURGOIGNIE J, Briggs J . Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285(21):2719-28. DOI: 10.1001/jama.285.21.2719. View

16.

Nissen S, Tuzcu E, Libby P, Thompson P, Ghali M, Garza D . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292(18):2217-25. DOI: 10.1001/jama.292.18.2217. View

17.

Vita J . Nitric oxide and vascular reactivity in African American patients with hypertension. J Card Fail. 2003; 9(5 Suppl Nitric Oxide):S199-204. DOI: 10.1054/s1071-9164(03)00588-8. View

18.

Tarver-Carr M, Powe N, Eberhardt M, LaVeist T, Kington R, Coresh J . Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002; 13(9):2363-70. DOI: 10.1097/01.asn.0000026493.18542.6a. View

19.

Hollenberg N, Parving H, Viberti G, Remuzzi G, Ritter S, Zelenkofske S . Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007; 25(9):1921-6. DOI: 10.1097/HJH.0b013e328277596e. View

20.

Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B . Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint.... Am Heart J. 2004; 148(1):52-61. DOI: 10.1016/j.ahj.2004.03.020. View